Liquidia Corporation (LQDA)
13.29
-0.43 (-3.13%)
At close: Apr 21, 2025, 3:59 PM
13.31
0.15%
After-hours: Apr 21, 2025, 04:52 PM EDT
Company Description
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States.
Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension.
It also distributes generic treprostinil injection in the United States.
Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
Liquidia Corporation

Country | United States |
IPO Date | Jul 26, 2018 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 170 |
CEO | Dr. Roger A. Jeffs Ph.D. |
Contact Details
Address: 419 Davis Drive Morrisville, North Carolina United States | |
Website | https://www.liquidia.com |
Stock Details
Ticker Symbol | LQDA |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001819576 |
CUSIP Number | 53635D202 |
ISIN Number | US53635D2027 |
Employer ID | 85-1710962 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Roger A. Jeffs Ph.D. | Chief Executive Officer & Director |
Michael Kaseta | Chief Operating Officer & Chief Financial Officer |
Dr. Ginger Denison | Co-Founder |
Dr. Rajeev Saggar M.D. | Chief Medical Officer |
Jason Adair | Chief Business Officer |
Michael Hunter | Senior Vice President of Manufacturing Operations |
Russell Schundler | General Counsel & Corporate Secretary |
Sarah Krepp SPHR | Senior Vice President of People & Culture |
Scott Moomaw | Chief Commercial Officer |
William R. Kenan Jr. | Co-Founder |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Apr 16, 2025 | 4 | Filing |
Apr 16, 2025 | 4 | Filing |
Apr 16, 2025 | 4 | Filing |
Apr 16, 2025 | 4 | Filing |
Apr 16, 2025 | 4 | Filing |
Apr 15, 2025 | 4 | Filing |
Mar 28, 2025 | 8-K | Current Report |
Mar 19, 2025 | S-3 | Filing |
Mar 19, 2025 | S-8 | Filing |
Mar 19, 2025 | S-8 | Filing |